Loading clinical trials...
Loading clinical trials...
Impact of GLP1-RAs on Inflammation and Endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 Trial
Conditions
Interventions
semaglutide
Standard Treatment (Guideline-Based)
Locations
2
Italy
Azienda Ospedaliera Sant'Anna e San Sebastiano
Caserta, Caserta, Italy
Federico II University
Naples, Napoli, Italy
Start Date
September 8, 2025
Primary Completion Date
March 8, 2027
Completion Date
March 8, 2027
Last Updated
January 2, 2026
NCT07321678
NCT06293417
NCT07172997
NCT06733805
NCT07537088
NCT07412015
Lead Sponsor
Federico II University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions